Avid Bioservices
CDMO

股本结构

单位：万股
公告日期 2024-12-10 2024-11-07 2024-12-10 2024-08-28 2024-08-28 2024-09-09
证券总股本 6396.33 6395.58 6395.60 6379.51 6379.06 6379.00
普通股本 6396.33 6395.58 6395.60 6379.51 6379.06 6379.00
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2024-12-03 2024-11-06 2024-10-31 2024-08-20 2024-08-15 2024-07-31
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2024-12-10 6396.33 未披露 定期报告 2024-12-03
2024-11-07 6395.58 未披露 定期报告 2024-11-06
2024-12-10 6395.60 未披露
更多>>
From July 31, 2024 to October 31, 2024 Common stock issued under equity compensation plans
2024-10-31
2024-08-28 6379.51 未披露 定期报告 2024-08-20
2024-08-28 6379.06 未披露 定期报告 2024-08-15
2024-09-09 6379.00 未披露
更多>>
From April 30, 2024 to July 31, 2024 Common stock issued under equity compensation plans
2024-07-31
2024-07-02 6358.11 未披露 定期报告 2024-06-24
2024-07-02 6356.80 未披露
更多>>
From April 30, 2023 to April 30, 2024 Common stock issued under equity compensation plans
2024-04-30
2024-04-24 6347.98 未披露 定期报告 2024-04-08
2024-04-24 6346.30 未披露
更多>>
From October 31, 2023 to January 31, 2024 Common stock issued under equity compensation plans
2024-01-31
2023-12-07 6323.92 未披露 定期报告 2023-11-27
2023-12-07 6323.40 未披露
更多>>
From July 31, 2023 to October 31, 2023 Common stock issued under equity compensation plans
2023-10-31
2023-09-07 6311.29 未披露 定期报告 2023-08-18
2023-08-28 6311.12 未披露 定期报告 2023-08-15
2023-09-07 6311.10 未披露
更多>>
From April 30, 2023 to July 31, 2023 Common stock issued under equity compensation plans
2023-07-31
2023-06-21 6272.92 未披露 定期报告 2023-06-09
2023-06-21 6269.20 未披露
更多>>
From April 30, 2022 to April 30, 2023 Common stock issued under equity compensation plans
2023-04-30
2023-03-13 6254.71 未披露 定期报告 2023-03-06
2023-03-13 6252.30 未披露
更多>>
From October 31, 2022 to January 31, 2023 Common stock issued under equity compensation plans
2023-01-31
2022-12-06 6230.94 未披露 定期报告 2022-11-28
2022-12-06 6230.80 未披露
更多>>
From July 31, 2022 to October 31, 2022 Common stock issued under equity compensation plans
2022-10-31
2022-08-29 6216.75 未披露 定期报告 2022-08-15
2022-09-06 6216.50 未披露
更多>>
From April 30, 2022 to July 31, 2022 Common stock issued under equity compensation plans
2022-07-31
2022-06-29 6183.47 未披露 定期报告 2022-06-17
2022-06-29 6180.70 未披露
更多>>
From April 30, 2021 to April 30, 2022 Common stock issued under equity compensation plans
2022-04-30
2021-03-08 6174.44 未披露 定期报告 2022-03-01
2022-03-08 6172.50 未披露
更多>>
From October 31, 2021 to January 31, 2022 Common stock issued under equity compensation plans
2022-01-31
2021-12-07 6158.15 未披露 定期报告 2021-12-01
2021-12-07 6155.20 未披露
更多>>
From July 31, 2021 to October 31, 2021 Common stock issued under equity compensation plans
2021-10-31
2021-08-27 6134.15 未披露 定期报告 2021-08-24
2021-08-27 6134.04 未披露 定期报告 2021-08-06
2021-09-08 6134.10 未披露
更多>>
From April 30, 2021 to July 31, 2021 Common stock issued under equity compensation plans
2021-07-31
2021-06-29 6109.77 未披露 定期报告 2021-06-18
2021-06-29 6106.90 未披露
更多>>
From April 30, 2020 To April 30, 2021 Conversion of Series E preferred stock to common stock Redemption of Series E preferred stock Common stock issued, net of issuance costs of $2,359 Common stock issued under equity compensation plans
2021-04-30
2021-03-08 6082.86 未披露 定期报告 2021-03-01
2021-03-08 6082.70 164.80
更多>>
From October 31, 2020 to January 31, 2021 Common stock issued, net of issuance of issuance costs of $2,359 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Common stock issued upon vesting of restricted stock units
2021-01-31
2020-12-14 6005.58 未披露
更多>>
1.Shares of common stock to be offered 3,333,335 shares of common stock. 2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 56,722,452 shares of common stock issued and outstanding as of October 31, 2020.
2020-12-14
2020-12-02 5672.63 未披露 定期报告 2020-11-23
2020-12-09 5672.25 164.80
更多>>
From July 31, 2020 to October 31, 2020 Exercise of stock options
2020-10-31
2020-08-27 5660.28 未披露 定期报告 2020-08-24
2020-08-27 5660.12 未披露 定期报告 2020-08-10
2020-09-01 5660.10 164.80
更多>>
From April 30, 2020 to July 31, 2020 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Vesting of restricted stock units
2020-07-31
2020-06-30 5651.13 未披露 定期报告 2020-06-19
2020-06-30 5648.30 164.80
更多>>
From April 30, 2019 to April 30, 2020 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Vesting of restricted stock units
2020-04-30
2020-03-10 5648.22 未披露 定期报告 2020-03-02
2020-03-10 5647.90 164.80
更多>>
from October 31, 2019 to January 31, 2020 Exercise of stock options Vesting of restricted stock units
2020-01-31
2019-12-09 5633.81 未披露 定期报告 2019-11-30
2019-12-09 5633.80 164.80
更多>>
from July 31, 2019 to October 31, 2019 Common stock issued under employee stock purchase plan Exercise of stock options
2019-10-31
2019-08-21 5623.77 164.78 定期报告 2019-08-02
2019-09-05 5623.80 164.80
更多>>
from April 30, 2019 to July 31, 2019 Vesting of restricted stock units Exercise of stock options
2019-07-31
2019-06-27 5613.77 未披露 定期报告 2019-06-14
2019-06-27 5613.57 164.78
更多>>
from April 30, 2018 to April 30, 2019 Common stock issued under Employee Stock Purchase Plan Exercise of stock options
2019-04-30
2019-03-11 5607.45 未披露 定期报告 2019-03-04
2019-03-11 5607.23 164.78 定期报告 2019-01-31
2018-12-10 5606.79 未披露 定期报告 2018-12-03
2018-12-10 5606.35 164.78 定期报告 2018-10-31
2018-09-10 5600.15 未披露 定期报告 2018-09-05
2018-09-10 5599.03 164.78 定期报告 2018-07-31
2018-07-16 5579.31 未披露 定期报告 2018-07-10
2018-07-16 5568.92 164.78
更多>>
From April 30, 2017 to April 30, 2018 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $111,000 Common stock issued for cash under February 14, 2018 Public Offering, net of issuance costs of $1,669,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Fractional shares issued pursuant to reverse stock split
2018-04-30
2018-03-12 5555.22 未披露 定期报告 2018-03-07
2018-03-12 4525.72 164.78 定期报告 2018-01-31
2018-01-12 4525.30 未披露 定期报告 2018-01-08
2017-12-11 4521.28 未披露 定期报告 2017-12-06
2017-12-07 4521.06 未披露 定期报告 2017-11-27
2017-12-11 4517.26 164.78 定期报告 2017-10-31
2017-08-28 4509.61 未披露 定期报告 2017-08-25
2017-09-11 4509.42 164.78 定期报告 2017-07-31
2017-07-14 4401.40 164.78
更多>>
from April 30, 2016 to July 10, 2017 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $58,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $487,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $340,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Peregrine Pharmaceuticals, Inc. has filed a Certificate of Amendment of Certificate of Incorporation (“Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a 1-for-7 reverse stock split of the Company’s issued and outstanding shares of common stock effective as of 5:00 p.m. Eastern Time on July 7, 2017. Accordingly, each shareholder of the Company’s common stock will receive one (1) new share of common stock for every seven (7) shares of common stock held immediately prior to the effective time of the reverse stock split.The Company’s common stock will open for trading on the NASDAQ Capital Market on July 10, 2017 on a split-adjusted basis.As a result of the reverse stock split, the number of issued and outstanding shares of the Company’s common stock will be adjusted from approximately 315 million to approximately 45 million shares. The number of authorized shares of the Company’s common stock under the Certificate of Incorporation remains the same.
2017-07-10
2017-03-13 29770.95 未披露 定期报告 2017-03-10
2017-03-13 27106.85 164.78 定期报告 2017-01-31
2016-12-12 25714.15 未披露 定期报告 2016-12-08
2016-12-12 25176.53 164.78 定期报告 2016-10-31
2016-09-08 24238.19 未披露 定期报告 2016-09-02
2016-09-08 24145.67 157.74 定期报告 2016-07-31
2016-07-14 24145.67 未披露 定期报告 2016-07-11
2016-07-14 23693.05 157.74
更多>>
from April 30, 2015 to April 30, 2016 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $1,000 Common stock issued for cash under June 13, 2014 Financing, net of issuance costs of $311,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $190,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $175,000 Common stock issued for cash under October 30, 2015 Financing, net of issuance costs of $1,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options
2016-04-30
2016-03-09 23373.84 未披露 定期报告 2016-03-08
2016-03-09 23223.12 157.74 定期报告 2016-01-31
2015-12-10 22970.18 未披露 定期报告 2015-12-09
2015-12-10 22582.46 157.74 定期报告 2015-10-31
2015-09-09 20212.40 未披露 定期报告 2015-09-04
2015-08-28 20137.74 未披露 定期报告 2015-08-21
2015-09-09 20098.39 157.48 定期报告 2015-07-31
2015-07-14 19993.49 未披露 定期报告 2015-07-10
2015-07-14 19334.66 157.48
更多>>
from April 30, 2014 to April 30, 2015 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $1,002,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $161,000 Common stock issued for cash under June 13, 2014 Financing, net of issuance costs of $352,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options
2015-04-30
2015-03-12 18833.29 未披露 定期报告 2015-03-06
2015-03-12 18424.47 118.00 定期报告 2015-01-31
2014-12-10 18208.12 未披露 定期报告 2014-12-05
2014-12-10 18200.06 117.79 定期报告 2014-10-31
2014-09-09 17950.54 未披露 定期报告 2014-09-05
2014-08-28 17922.64 未披露 定期报告 2014-08-22
2014-09-09 17921.60 117.50 定期报告 2014-07-31
2014-07-14 17920.95 未披露 定期报告 2014-07-07
2014-07-14 17887.12 77.50
更多>>
from April 30, 2013 to April 30, 2014 Series E preferred stock issued for cash under February 11, 2014 Offering, net of issuance costs of $1,458,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $1,504,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Common stock issued under restricted stock awards
2014-04-30
2014-03-07 17648.11 未披露 定期报告 2014-03-03
2014-03-07 17645.33 未披露 定期报告 2014-01-31
2013-12-27 16032.72 未披露 定期报告 2013-12-20
2013-12-10 16032.59 未披露 定期报告 2013-12-06
2013-12-10 16024.87 未披露 定期报告 2013-10-31
2013-09-09 15646.11 未披露 定期报告 2013-09-05
2013-08-26 15519.74 未披露 定期报告 2013-08-22
2013-09-09 15350.68 未披露 定期报告 2013-07-31
2013-07-11 15160.28 未披露 定期报告 2013-07-05
2013-07-11 14376.89 未披露
更多>>
from April 30, 2012 to April 30, 2013 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $895,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $337,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Common stock issued upon exercise of warrants
2013-04-30
2013-03-12 13711.08 未披露 定期报告 2013-03-11
2013-03-12 13377.06 未披露 定期报告 2013-01-31
2012-12-10 13253.98 未披露 定期报告 2012-12-07
2012-12-10 12331.02 未披露 定期报告 2012-10-31
2012-08-27 10419.12 未披露 定期报告 2012-08-22
2012-09-10 10417.84 未披露 定期报告 2012-07-31
2012-07-16 10417.41 未披露 定期报告 2012-07-13
2012-07-16 10142.14 未披露
更多>>
from April 30, 2011 to April 30, 2012 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $626,000 Common stock issued for cash under September 2, 2011 registered direct offering, net of issuance costs of $525,000 Common stock issued under Employee Stock Purchase Plan
2012-04-30
2012-03-09 9887.32 未披露 定期报告 2012-02-29
2012-03-09 9314.62 未披露 定期报告 2012-01-31
2011-12-12 8678.88 未披露 定期报告 2011-12-09
2011-12-12 8263.82 未披露 定期报告 2011-10-31
2011-09-09 7953.63 未披露 定期报告 2011-09-08
2011-09-09 7174.97 未披露 定期报告 2011-07-31
2011-07-14 7106.99 未披露 定期报告 2011-07-08
2011-07-14 6983.71 未披露
更多>>
from April 30 2010 to April 30, 2011 Common stock issued for cash under July 14, 2009 Financing, net of issuance costs of $133,000 Common stock issued for cash under June 22, 2010 Financing, net of issuance costs of $345,000 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $291,000 Common stock issued upon exercise of options Common stock issued upon exercise of warrants Common stock issued for services Common stock issued under restricted stock awards Common stock issued under Employee Stock Purchase Plan
2011-04-30
2011-03-11 6788.58 未披露 定期报告 2011-02-28
2011-03-11 6681.34 未披露 定期报告 2011-01-31
2010-12-09 6393.24 未披露 定期报告 2010-11-30
2010-12-09 5922.07 未披露 定期报告 2010-10-31
2010-09-09 5619.03 未披露 定期报告 2010-08-31
2010-09-09 5578.50 未披露 定期报告 2010-07-31
2010-07-14 5506.94 未披露 定期报告 2010-07-09
2010-07-14 5309.49 未披露
更多>>
from Apr 30 2009 to Apr 30 2010 Common stock issued for cash under March 26, 2009 Financing, net of issuance costs of $305,000 Common stock issued for cash under July 14, 2009 Financing, net of issuance costs of $545,000 Common stock issued upon exercise of options Fractional shares issued pursuant to reverse stock split
2010-04-30
2010-03-11 5144.60 未披露 定期报告 2010-03-01
2010-03-11 5090.34 未披露 定期报告 2010-01-31
2009-07-14 23696.44 未披露 定期报告 2009-07-10
2009-07-14 22768.86 未披露
更多>>
from April 30, 2008 to April 30, 2009 Common stock issued for cash under March 26, 2009 Financing, net of issuance costs of $58,000
2009-04-30
2008-07-14 22621.06 未披露
更多>>
from April 30, 2007 to April 30, 2008 Common stock issued for cash under June 28, 2007 Financing, net of issuance costs of $1,641,000 Common stock issued upon exercise of options Common stock issued upon exercise of warrants, net of issuance costs of nil
2008-04-30
2007-07-11 22616.56 未披露 定期报告 2007-07-06
2007-07-11 19611.22 未披露
更多>>
from April 30, 2006 to April 30, 2007 Common stock issued for cash under June 16, 2006 Financing, net of issuance costs of $30,000 Common stock issued to various unrelated entities for prepaid research services Common stock issued upon exercise of options Common stock issued upon exercise of warrants, net of issuance costs of $16,000 Common stock issued under stock bonus plan
2007-04-30
2006-07-14 18885.22 未披露 定期报告 2006-07-07
2006-07-14 17938.22 未披露
更多>>
from April 30, 2005 to April 30, 2006 Common stock issued for cash under January 31, 2005 Financing, net of issuance costs of $6,000 Common stock issued for cash under May 11, 2005 Financing, net of issuance costs of $11,000 Common stock issued for cash under June 22, 2005 Financing, net of issuance costs of $29,000 Common stock issued for cash under November 23, 2005 Financing, net of issuance costs of $1,000 Common stock issued for cash under April 5, 2006 Financing, net of issuance costs of $1,000 Common stock issued to various unrelated entities for research services Common stock issued upon exercise of options and warrants Common stock issued under the Company's stock bonus plan
2006-04-30
2005-07-14 16569.07 未披露 定期报告 2005-07-06
2005-07-14 15298.35 未披露
更多>>
from April 30, 2004 to April 30, 2005 Common stock issued for cash under March 31, 2004 Financing, net of issuance costs of $43,000 Common stock issued for cash under January 31, 2005 Financing, net of issuance costs of $1,000 Common stock issued to various unrelated entities for research services Common stock issued upon exercise of options and warrants, net of issuance costs of $5,000
2005-04-30
2004-07-14 14126.82 未披露
更多>>
from April 30, 2003 to April 30, 2004 Common stock issued for cash under June 6, 2003 Financing, net of issuance costs of $104,000 Common stock issued for cash under June 26, 2003 Financing, net of issuance costs of $101,000 Common stock issued for cash under option granted under June 26, 2003 Financing, net of issuance costs of $54,000 Common stock issued for cash under July 24, 2003 Financing, net of issuance costs of $13,000 Common stock issued for cash under September 18, 2003 Financing, net of issuance costs of $19,000 Common stock issued for cash under November 17, 2003 Financing, net of issuance costs of $1,000 Common stock issued for cash under January 22, 2004 Financing, net of issuance costs of $1,000 Common stock issued to Aeres Biomedical Ltd for research services under a research collaboration agreement, net of issuance costs of under $1,000 Common stock issued upon conversion of convertible debt Common stock issued upon exercise of options and warrants, net of issuance costs of $134,000
2004-04-30
2003-07-29 12985.57 未披露 定期报告 2003-07-18
2003-07-29 11960.05 未披露
更多>>
from APRIL 30, 2002 to APRIL 30, 2003 Common stock issued for cash under Securities Purchase Agreement, net of issuance costs of $341,000 Common stock issued for cash under Shelf File No. 333-71086, net of issuance costs of $190,000 Common stock issued upon conversion of convertible debt, net of issuance cost of $17,000 Common stock issued for cash upon exercise of options Rescind prior sale of common stock to related party
2003-04-30
2002-08-13 11027.52 未披露
更多>>
from APRIL 30, 2001 to APRIL 30, 2002 Common stock issued for cash under Equity Line, net of cash offering costs of $478,000 Common stock issued for cash upon exercise of options and warrants Common stock issued for cash under Shelf, net of cash offering costs of $87,000
2002-04-30
2001-07-27 9998.98 未披露 定期报告 2001-07-19
2001-07-27 9728.89 未披露
更多>>
from APRIL 30, 2000 to APRIL 30, 2001 Common stock issued for cash under Equity Line, net of offering costs of $728,000 Common stock issued upon conversion of Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued to OXiGENE, Inc. for cash under joint venture Common stock issued to Schering A.G. for obligations under the license agreement amendment Common stock issued for cash to SuperGen, Inc. under license agreement
2001-04-30
2000-07-31 9471.18 未披露 定期报告 2000-07-21
2000-07-31 9061.26 未披露
更多>>
from APRIL 30, 1999 to APRIL 30, 2000 Common stock issued upon conversion of Class C preferred stock Common stock issued for cash under Equity Line Agreement, net of offering costs of $781,000 Common stock issued for cash under Subscription Agreement with Related Parties Common stock issued upon conversion of Class C warrants and Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued for services, license rights, interest, and under severance agreements
2000-04-30
1999-07-28 7636.98 未披露 定期报告 1999-07-15
1999-07-28 7337.22 0.01
更多>>
from APRIL 30, 1998 to APRIL 30, 1999 Preferred stock issued upon exercise of Class C Placement Agent Warrant Common stock issued upon conversion of Class C preferred stock Common stock issued for cash under Equity Line Agreement, net of offering costs of $678,000 Common stock issued upon conversion of Class C warrants and Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued for services, license rights, interest, and under severance agreements
1999-04-30
1998-07-29 6298.92 未披露 定期报告 1998-07-23
1998-07-29 4854.74 0.48
更多>>
from APRIL 30, 1997 to APRIL 30, 1998 Accretion of Class B and Class C preferred stock dividends and discount Preferred stock issued upon exercise of Class C Placement Agent Warrant, net of offering costs of offering costs of $115,193 applicable to Class C financing Additional consideration on Class C preferred stock Common stock issued upon conversion of Class B and Class C preferred stock Common stock issued for cash and upon exercise of options and warrants Common stock issued for services and interest
1998-04-30
1997-07-29 2725.47 未披露 定期报告 1997-07-01
1997-07-29 2724.87 1.42
更多>>
from April 30, 1996 to April 30, 1997 Class C preferred stock issued for cash,net of issuance costs of $931,029 Common stock issued upon conversionof Class B preferred stock Common stock issued for acquisition of subsidiary Common stock issued upon exercise of stock options
1997-04-30
1996-07-26 2086.97 未披露 定期报告 1996-07-01
1996-07-26 2004.80 0.68
更多>>
from April 30,1995 to April 30, 1996 Common stock issued for cash Class B preferred stock issued for cash, net of issuance costs of $1,062,456 Common stock issued upon conversion of Class A preferred stock Common stock issued upon conversion of Class B preferred stock Common stock issued upon conversion of note payable and accrued interest to related party Common stock issued upon conversion of accrued expenses and other current liabilities Common stock issued upon exercise of stock options Common stock issued upon exercise of stock options in exchange for services
1996-04-30
From July 31, 2024 to October 31, 2024 Common stock issued under equity compensation plans
From April 30, 2024 to July 31, 2024 Common stock issued under equity compensation plans
From April 30, 2023 to April 30, 2024 Common stock issued under equity compensation plans
From October 31, 2023 to January 31, 2024 Common stock issued under equity compensation plans
From July 31, 2023 to October 31, 2023 Common stock issued under equity compensation plans
From April 30, 2023 to July 31, 2023 Common stock issued under equity compensation plans
From April 30, 2022 to April 30, 2023 Common stock issued under equity compensation plans
From October 31, 2022 to January 31, 2023 Common stock issued under equity compensation plans
From July 31, 2022 to October 31, 2022 Common stock issued under equity compensation plans
From April 30, 2022 to July 31, 2022 Common stock issued under equity compensation plans
From April 30, 2021 to April 30, 2022 Common stock issued under equity compensation plans
From October 31, 2021 to January 31, 2022 Common stock issued under equity compensation plans
From July 31, 2021 to October 31, 2021 Common stock issued under equity compensation plans
From April 30, 2021 to July 31, 2021 Common stock issued under equity compensation plans
From April 30, 2020 To April 30, 2021 Conversion of Series E preferred stock to common stock Redemption of Series E preferred stock Common stock issued, net of issuance costs of $2,359 Common stock issued under equity compensation plans
From October 31, 2020 to January 31, 2021 Common stock issued, net of issuance of issuance costs of $2,359 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Common stock issued upon vesting of restricted stock units
1.Shares of common stock to be offered 3,333,335 shares of common stock. 2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 56,722,452 shares of common stock issued and outstanding as of October 31, 2020.
From July 31, 2020 to October 31, 2020 Exercise of stock options
From April 30, 2020 to July 31, 2020 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Vesting of restricted stock units
From April 30, 2019 to April 30, 2020 Common stock issued under Employee Stock Purchase Plan Exercise of stock options Vesting of restricted stock units
from October 31, 2019 to January 31, 2020 Exercise of stock options Vesting of restricted stock units
from July 31, 2019 to October 31, 2019 Common stock issued under employee stock purchase plan Exercise of stock options
from April 30, 2019 to July 31, 2019 Vesting of restricted stock units Exercise of stock options
from April 30, 2018 to April 30, 2019 Common stock issued under Employee Stock Purchase Plan Exercise of stock options
From April 30, 2017 to April 30, 2018 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $111,000 Common stock issued for cash under February 14, 2018 Public Offering, net of issuance costs of $1,669,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Fractional shares issued pursuant to reverse stock split
from April 30, 2016 to July 10, 2017 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $58,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $487,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $340,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Peregrine Pharmaceuticals, Inc. has filed a Certificate of Amendment of Certificate of Incorporation (“Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a 1-for-7 reverse stock split of the Company’s issued and outstanding shares of common stock effective as of 5:00 p.m. Eastern Time on July 7, 2017. Accordingly, each shareholder of the Company’s common stock will receive one (1) new share of common stock for every seven (7) shares of common stock held immediately prior to the effective time of the reverse stock split.The Company’s common stock will open for trading on the NASDAQ Capital Market on July 10, 2017 on a split-adjusted basis.As a result of the reverse stock split, the number of issued and outstanding shares of the Company’s common stock will be adjusted from approximately 315 million to approximately 45 million shares. The number of authorized shares of the Company’s common stock under the Certificate of Incorporation remains the same.
from April 30, 2015 to April 30, 2016 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $1,000 Common stock issued for cash under June 13, 2014 Financing, net of issuance costs of $311,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $190,000 Common stock issued for cash under August 7, 2015 Financing, net of issuance costs of $175,000 Common stock issued for cash under October 30, 2015 Financing, net of issuance costs of $1,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options
from April 30, 2014 to April 30, 2015 Series E preferred stock issued for cash under June 13, 2014 Financing, net of issuance costs of $1,002,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $161,000 Common stock issued for cash under June 13, 2014 Financing, net of issuance costs of $352,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options
from April 30, 2013 to April 30, 2014 Series E preferred stock issued for cash under February 11, 2014 Offering, net of issuance costs of $1,458,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $1,504,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Common stock issued under restricted stock awards
from April 30, 2012 to April 30, 2013 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $895,000 Common stock issued for cash under December 27, 2012 Financing, net of issuance costs of $337,000 Common stock issued under Employee Stock Purchase Plan Common stock issued upon exercise of options Common stock issued upon exercise of warrants
from April 30, 2011 to April 30, 2012 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $626,000 Common stock issued for cash under September 2, 2011 registered direct offering, net of issuance costs of $525,000 Common stock issued under Employee Stock Purchase Plan
from April 30 2010 to April 30, 2011 Common stock issued for cash under July 14, 2009 Financing, net of issuance costs of $133,000 Common stock issued for cash under June 22, 2010 Financing, net of issuance costs of $345,000 Common stock issued for cash under December 29, 2010 Financing, net of issuance costs of $291,000 Common stock issued upon exercise of options Common stock issued upon exercise of warrants Common stock issued for services Common stock issued under restricted stock awards Common stock issued under Employee Stock Purchase Plan
from Apr 30 2009 to Apr 30 2010 Common stock issued for cash under March 26, 2009 Financing, net of issuance costs of $305,000 Common stock issued for cash under July 14, 2009 Financing, net of issuance costs of $545,000 Common stock issued upon exercise of options Fractional shares issued pursuant to reverse stock split
from April 30, 2008 to April 30, 2009 Common stock issued for cash under March 26, 2009 Financing, net of issuance costs of $58,000
from April 30, 2007 to April 30, 2008 Common stock issued for cash under June 28, 2007 Financing, net of issuance costs of $1,641,000 Common stock issued upon exercise of options Common stock issued upon exercise of warrants, net of issuance costs of nil
from April 30, 2006 to April 30, 2007 Common stock issued for cash under June 16, 2006 Financing, net of issuance costs of $30,000 Common stock issued to various unrelated entities for prepaid research services Common stock issued upon exercise of options Common stock issued upon exercise of warrants, net of issuance costs of $16,000 Common stock issued under stock bonus plan
from April 30, 2005 to April 30, 2006 Common stock issued for cash under January 31, 2005 Financing, net of issuance costs of $6,000 Common stock issued for cash under May 11, 2005 Financing, net of issuance costs of $11,000 Common stock issued for cash under June 22, 2005 Financing, net of issuance costs of $29,000 Common stock issued for cash under November 23, 2005 Financing, net of issuance costs of $1,000 Common stock issued for cash under April 5, 2006 Financing, net of issuance costs of $1,000 Common stock issued to various unrelated entities for research services Common stock issued upon exercise of options and warrants Common stock issued under the Company's stock bonus plan
from April 30, 2004 to April 30, 2005 Common stock issued for cash under March 31, 2004 Financing, net of issuance costs of $43,000 Common stock issued for cash under January 31, 2005 Financing, net of issuance costs of $1,000 Common stock issued to various unrelated entities for research services Common stock issued upon exercise of options and warrants, net of issuance costs of $5,000
from April 30, 2003 to April 30, 2004 Common stock issued for cash under June 6, 2003 Financing, net of issuance costs of $104,000 Common stock issued for cash under June 26, 2003 Financing, net of issuance costs of $101,000 Common stock issued for cash under option granted under June 26, 2003 Financing, net of issuance costs of $54,000 Common stock issued for cash under July 24, 2003 Financing, net of issuance costs of $13,000 Common stock issued for cash under September 18, 2003 Financing, net of issuance costs of $19,000 Common stock issued for cash under November 17, 2003 Financing, net of issuance costs of $1,000 Common stock issued for cash under January 22, 2004 Financing, net of issuance costs of $1,000 Common stock issued to Aeres Biomedical Ltd for research services under a research collaboration agreement, net of issuance costs of under $1,000 Common stock issued upon conversion of convertible debt Common stock issued upon exercise of options and warrants, net of issuance costs of $134,000
from APRIL 30, 2002 to APRIL 30, 2003 Common stock issued for cash under Securities Purchase Agreement, net of issuance costs of $341,000 Common stock issued for cash under Shelf File No. 333-71086, net of issuance costs of $190,000 Common stock issued upon conversion of convertible debt, net of issuance cost of $17,000 Common stock issued for cash upon exercise of options Rescind prior sale of common stock to related party
from APRIL 30, 2001 to APRIL 30, 2002 Common stock issued for cash under Equity Line, net of cash offering costs of $478,000 Common stock issued for cash upon exercise of options and warrants Common stock issued for cash under Shelf, net of cash offering costs of $87,000
from APRIL 30, 2000 to APRIL 30, 2001 Common stock issued for cash under Equity Line, net of offering costs of $728,000 Common stock issued upon conversion of Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued to OXiGENE, Inc. for cash under joint venture Common stock issued to Schering A.G. for obligations under the license agreement amendment Common stock issued for cash to SuperGen, Inc. under license agreement
from APRIL 30, 1999 to APRIL 30, 2000 Common stock issued upon conversion of Class C preferred stock Common stock issued for cash under Equity Line Agreement, net of offering costs of $781,000 Common stock issued for cash under Subscription Agreement with Related Parties Common stock issued upon conversion of Class C warrants and Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued for services, license rights, interest, and under severance agreements
from APRIL 30, 1998 to APRIL 30, 1999 Preferred stock issued upon exercise of Class C Placement Agent Warrant Common stock issued upon conversion of Class C preferred stock Common stock issued for cash under Equity Line Agreement, net of offering costs of $678,000 Common stock issued upon conversion of Class C warrants and Equity Line warrants Common stock issued for cash upon exercise of options and warrants Common stock issued for services, license rights, interest, and under severance agreements
from APRIL 30, 1997 to APRIL 30, 1998 Accretion of Class B and Class C preferred stock dividends and discount Preferred stock issued upon exercise of Class C Placement Agent Warrant, net of offering costs of offering costs of $115,193 applicable to Class C financing Additional consideration on Class C preferred stock Common stock issued upon conversion of Class B and Class C preferred stock Common stock issued for cash and upon exercise of options and warrants Common stock issued for services and interest
from April 30, 1996 to April 30, 1997 Class C preferred stock issued for cash,net of issuance costs of $931,029 Common stock issued upon conversionof Class B preferred stock Common stock issued for acquisition of subsidiary Common stock issued upon exercise of stock options
from April 30,1995 to April 30, 1996 Common stock issued for cash Class B preferred stock issued for cash, net of issuance costs of $1,062,456 Common stock issued upon conversion of Class A preferred stock Common stock issued upon conversion of Class B preferred stock Common stock issued upon conversion of note payable and accrued interest to related party Common stock issued upon conversion of accrued expenses and other current liabilities Common stock issued upon exercise of stock options Common stock issued upon exercise of stock options in exchange for services
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。